Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider John Maraganore Purchases 9,411 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director John Maraganore bought 9,411 shares of Rapport Therapeutics stock in a transaction on Thursday, October 22nd. The stock was purchased at an average price of $26.45 per share, for a total transaction of $248,920.95. Following the completion of the acquisition, the director owned 9,411 shares in the company, valued at $248,920.95. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Rapport Therapeutics Stock Performance

RAPP stock opened at $25.93 on Friday. Rapport Therapeutics, Inc. has a 52-week low of $23.75 and a 52-week high of $52.93. The stock’s fifty day simple moving average is $39.01 and its 200-day simple moving average is $38.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Equities research analysts predict that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Institutional Trading of Rapport Therapeutics

Hedge funds have recently bought and sold shares of the company. KBC Group NV acquired a new position in Rapport Therapeutics during the first quarter valued at $30,000. Sterling Capital Management LLC lifted its stake in Rapport Therapeutics by 597.9% in the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after acquiring an additional 843 shares in the last quarter. State of Wyoming purchased a new stake in Rapport Therapeutics in the 2nd quarter worth about $65,000. Meeder Asset Management Inc. acquired a new stake in Rapport Therapeutics during the 2nd quarter worth about $116,000. Finally, AlphaCentric Advisors LLC boosted its position in Rapport Therapeutics by 6.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after acquiring an additional 408 shares during the period.

Wall Street Analysts Forecast Growth

RAPP has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their target price on shares of Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. Raymond James Financial reissued a “strong-buy” rating and issued a $86.00 price objective on shares of Rapport Therapeutics in a report on Tuesday. BTIG Research lifted their price objective on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Guggenheim increased their target price on shares of Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.